Phase 1 study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in locally advanced squaous cell carcinoma of the head and neck (LA SCCHN).

Le résumé fourni par la source

e18085 Background: Despite advances in therapy, overall survival for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) remains suboptimal, with 5-year survival rates depending on HPV status which indicates a need for additional therapeutic approaches. We sought to improve outcomes by adding immunotherapy to induction chemotherapy with cisplatin and docetaxel (TP). ICI potentially is a less toxic and more efficacious alternative to traditional chemotherapy induction regimens. Methods: In this phase 1, non-randomized study (NCT05376553), patients with previously untreated stage IV LA SCCHN were enrolled into two cohorts. Cohort A received cisplatin (100 mg/m²) and docetaxel (75 mg/m²) on day 1 followed by cemiplimab (350 mg) on day 14 for three cycles; Cohort B received cemiplimab every 3 weeks starting on day −7. Patients then underwent standard-of-care surgery and/or concurrent chemoradiation, followed by adjuvant cemiplimab every 3 weeks for eight cycles. Cemiplimab was combined with TP using a standard 3+3 design without dose escalation. Dose-limiting toxicities attributable to cemiplimab were assessed in cycle 1. Twenty-four patients were enrolled with primary tumors in the oropharynx (15; HPV+ 9), larynx (2), oral cavity (3), nasopharynx (1; HPV+), and hypopharynx (3). Results: 24 eligible patients-initiated therapy and all completed ICI and have completed the study.1 death occurred during follow up period unrelated to study drug or disease. 2 deaths due to progression of disease; 4 patients experienced progression of disease, and 1 patient was lost to follow up. 16/24 (67%) of patients who completed the study remain alive in remission. Of among the 24 patients, that completed ICI the overall response rate (ORR) was 83.33% with 4 partial responses, 14 complete responses, and 6 progressions of disease. The disease control rate is 83.33%, with a relapse rate of 18.18%. 5/5 oral cancer patients underwent resection, 3 had complete pathological response, 1 with 85% pathological tumor necrosis and 1 had a minimal pathological response <10%. There was no dose limiting toxicities The median duration follow-up was 21 months. Conclusions: Induction with ICI with cemiplimab combined with cisplatin and docetaxel was feasible and demonstrated an acceptable safety profile in patients with LA SCCHN, indicating a high ORR and disease control rate. These phase I results support further investigation in larger studies. Clinical trial information: NCT05376553 .

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.